See Credit Details Below
Overview
The unprecedented disruption businesses face from the impact of COVID-19 on their operations and finances, as well as on the overall economy, have created complex and intricate challenges in goodwill impairment testing processes. Companies face issues ranging from determining whether interim goodwill impairment tests should be performed to assessing the impact of stock price declines on impairment testing. Join PJ Patel of Valuation Research Corporation and SEC Institute workshop leaders Robert Laux and George M. Wilson as they provide a deep-dive discussion into the goodwill impairment testing challenges created by COVID-19 in the current period.
In this Briefing, participants will:
- Understand the issues in determining whether an interim impairment test should be performed
- Review the issues in situations where the carrying value of a company’s reporting units exceeds the company’s market capitalization
- Enumerate the changes necessary to impairment testing and fair value measurement created by the disruption and uncertainty from COVID-19
Program Level: Update
Intended Audience: Accountants and attorneys who deal with SEC reporting and disclosure and related accounting issues, including CFOs, controllers and their staff, internal auditors, partners of public accounting firms and their staff, in-house counsel and outside attorneys
Prerequisites: None
Advanced Preparation: None